The Metastatic Brain Tumor drugs in development market research report provides comprehensive information on the therapeutics under development for Metastatic Brain Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Metastatic Brain Tumor. Buy the report here.

Smarter leaders trust GlobalData

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Metastatic Brain Tumor and features dormant and discontinued products.

GlobalData tracks 64 drugs in development for Metastatic Brain Tumor by 55 companies/universities/institutes. The top development phase for Metastatic Brain Tumor is phase ii with 21 drugs in that stage. The Metastatic Brain Tumor pipeline has 62 drugs in development by companies and two by universities/ institutes. Some of the companies in the Metastatic Brain Tumor pipeline products market are: AngioChem, Pfizer and Praesidia Biotherapeutics.

The key targets in the Metastatic Brain Tumor pipeline products market include Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2.7.10.1), Epidermal Growth Factor Receptor (Proto Oncogene c ErbB 1 or Receptor Tyrosine Protein Kinase erbB 1 or HER1 or ERBB1 or EGFR or EC 2.7.10.1), and Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22).

The key mechanisms of action in the Metastatic Brain Tumor pipeline product include Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2 (Metastatic Lymph Node Gene 19 Protein or Proto Oncogene Neu or Proto Oncogene C ErbB 2 or Tyrosine Kinase Type Cell Surface Receptor HER2 or p185erbB2 or HER2 or CD340 or ERBB2 or EC 2 with seven drugs in Phase II. The Metastatic Brain Tumor pipeline products include 11 routes of administration with the top ROA being Oral and 11 key molecule types in the Metastatic Brain Tumor pipeline products market including Small Molecule, and Monoclonal Antibody Conjugated.

Metastatic Brain Tumor overview

Metastatic brain tumors, also known as secondary brain tumors, occur when cancer cells spread to the brain from a primary cancer elsewhere in the body. These tumors are more common than primary brain tumors, arising from cancers originating in other organs such as the lungs, breast, colon, or skin (melanoma) and then migrating to the brain through the bloodstream or lymphatic system. When cancer cells reach the brain and form tumors, they disrupt normal brain function and can cause a variety of symptoms, including headaches, seizures, nausea or vomiting, changes in vision or hearing, weakness or numbness in the extremities, changes in cognitive abilities or personality, and difficulty with balance or coordination. Diagnosis of metastatic brain tumors typically involves imaging tests such as MRI or CT scans to visualize the tumors and determine their location, size, and number. Biopsies may be performed to confirm the origin of the tumors and guide treatment decisions.

For a complete picture of Metastatic Brain Tumor’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.